ArticleBreast cancer research : BCR2026
Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundParaneoplastic neurological syndromes (PNSs) are rare autoimmune diseases that occur in the context of cancer, but the mechanisms leading to immune tolerance breakdown remain unknown. Breast cancers (BCs) associated with Yo-PNS and Ri-PNS show distinct immune and genetic specificities, suggesting that tumour characteristics may contribute to autoimmunity. Herein, we aimed to investigate whether PNS-associated BCs display additional specificities, including stromal and vascular features that have not been systematically assessed.
methodsWe compared 12 BCs associated with Yo-PNS (Yo-BCs) and 10 BCs associated with Ri-PNS (Ri-BCs) with two independent cohorts of non-PNS breast cancer controls (CtrlYo and CtrlRi) using tumour transcriptomic profiling with a targeted 760-gene panel and complementary immunohistochemistry.
resultsTranscriptomic analysis identified 27 genes commonly differentially expressed in Yo-BCs and Ri-BCs compared with their respective controls, including upregulation of FLT4. Immunohistochemistry confirmed increased podoplanin-positive lymphatic structures in both Yo-BCs and Ri-BCs. In parallel, Yo-BCs showed predominant mesenchymal phenotype and downregulation of genes associated with hypoxia (HIF1A, FLT1, LDHA, P4HA2) compared with CtrlYo. These features were not present in Ri-BCs when compared with CtrlRi.
conclusionThese findings not only highlight subtype-specificities of Yo- and Ri-associated BCs, but also identify lymphangiogenesis as a shared tumour-intrinsic feature that may be part of a cancer-specific context required to initiate or sustain autoimmunity in PNS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.